Skip to main content
Free trial

Ask AI to review this stock

Copy the prompt to get recent events, historical reactions, and a short research brief.

Tell your AI:

Help me set up FinLab and analyze 4102 永日. Please read: https://finlab.finance/en/setup?stock=4102

No install, open FinLab Studio

4102

永日 Biotech & Healthcare As of 2026-06-17 Updated daily after market close

quality needs a look, fair valuation.

1 active signal
Revenue ≥20%
This page refreshes daily after the close. Add 永日 to your watchlist to track signal changes on your next visit.
Valuation 40Quality 35Growth 72Momentum 24Chips 48

Is 永日 a buy? Fundamentals and valuation first

  • Weak profitability.Operating margin is in the 36th market percentile. Latest quarterly ROE ≈ 0.7%.

  • Valuation is neutral.PE is in the 63th market percentile; within its own history, PE is around the 38th percentile.

  • Foreign investors are net buying.Foreign 20-day net flow ≈ 0.2% of volume (net buy).

  • Strong revenue growth.Latest monthly revenue YoY ≈ 27.7%, above the 20% growth threshold.

  • Signals are active now.On the latest data, signals such as Revenue YoY ≥ 20% are active — see the historical forward returns after each occurrence below.

Chip flow

Bullish +0.66
BearishNeutralBullish

Single-sided accumulation, concentration rising — bullish

  • Single-sided accumulation, concentration rising — bullish
  • 元大-大甲 holds 326 lots
  • sellers have 248 lots left, ~125 sessions to clear

Window from 2026-01-17 · Price -7% · branches to 2026-06-17· TDCC to 2026-06-12

  • Largest holder 元大-大甲 has accumulated 326 lots since the start (sold 1%), now trimming.
  • Main distributor 國泰-敦南 peaked at 226 lots, has sold 31%, 157 left, ~40 sessions to clear at the recent pace.
  • TDCC big holders (absolute) >1000-lot holders +0.48pp, mid holders +2, retail -2.39pp — concentration shifting upward.
  • Foreign hedge-desk net short Net short -139 lots (inferred from branch profile, mostly hedging — not necessarily bearish, not case-confirmed).
Branch inventory reconstruction
Accumulating holders Branches that accumulated shares during the window and still hold positive inventory; they are the absorbing side.
Distributing sellers Branches that built inventory earlier and have been selling it down; the remaining number estimates what has not cleared.
Net-short desks Trading-desk branches with negative inventory or net selling, often hedge, offsetting, or short-term flow. It is not automatically a bearish view.
Accumulating
元大-大甲元大-中崙富邦-竹東元大-八德凱基-汐止兆豐-城中
Distributing
國泰-敦南富邦-仁愛新光玉山-景美元大-豐原站前華南永昌-彰化
Desks
own scale
新光-新竹富邦-竹北永豐金-新店凱基-台北
Price Accumulating & Distributing share one scale (comparable); Desks is independent. Zero is the baseline
Branch details Unit: lots

Accumulating

  • 元大-大甲 +326
    sold 1%
  • 元大-中崙 +208
    sold 0%
  • 富邦-竹東 +138
    sold 0%· still adding
  • 元大-八德 +136
    sold 0%
  • 凱基-汐止 +132
    sold 15%
  • 兆豐-城中 +110
    sold 0%

Distributing

  • 國泰-敦南 157 left
    sold 31%· ~40 sessions to clear
  • 富邦-仁愛 7 left
    sold 89%· paused recently
  • 新光 25 left
    sold 49%· ~125 sessions to clear
  • 玉山-景美 29 left
    sold 28%· ~73 sessions to clear
  • 元大-豐原站前 18 left
    sold 51%· paused recently
  • 華南永昌-彰化 20 left
    sold 33%· paused recently

Desks

  • 新光-新竹 -380
    unclassified
  • 富邦-竹北 -157
    unclassified
  • 永豐金-新店 -149
    unclassified
  • 凱基-台北 -136
    day-trade · selling pressure
Still selling 248 lots ~125 sessions to bottom at most
Recent buy/sell force +460 absorbed / -70 sold buyers slightly ahead
Hedge-desk net short -1 lots potential cover-buying, not selling pressure
TDCC big holders · absolute-holding cross-check
>1000-lot holder share Retail (<400 lots) share Price (right axis)

Direction matches: big-holder share rose while retail share fell.

Describes chip flow, not investment advice. Branch data discloses only high-volume branches with ~1-day lag; TDCC is weekly. Inventory is a relative reconstruction from the window start, not absolute holdings.

Historical evidence

Signals active now

These signals are true on the latest data, with this stock's own historical forward-return stats after each occurrence.

Monthly revenue YoY ≥ 20% (from filing deadline)

Active · now 27.68%

Monthly revenue YoY ≥ 20%; event date is the first trading day after the filing deadline (no look-ahead).

67 historical occurrences (since 2007-04-23)
Average forward return after Monthly revenue YoY ≥ 20% (from filing deadline)。20-day: Win 45.5%, Sample 66, Median -0.52%, Excess +1.02%, Beat mkt rate 43.9%；60-day: Win 50%, Sample 66, Median -0.88%, Excess +2.55%, Beat mkt rate 39.4%；120-day: Win 41.5%, Sample 65, Median -2.07%, Excess +1.05%, Beat mkt rate 38.5%

120 days after: historical avg +11.32%

20-day +2.19%
60-day +8.45%
120-day +11.32%
20-day
60-day
120-day
Win
45.5%
50%
41.5%
Sample
66
66
65
Median
-0.52%
-0.88%
-2.07%
Excess
+1.02%
+2.55%
+1.05%
Beat mkt rate
43.9%
39.4%
38.5%

Over 65 occurrences, 120-day forward avg gained 11.32%, beat the market by 1.05 pts; win rate 41.5%.

Valuation regime and subsequent returns

Each day's PE is converted to its own-history percentile (as of that day), then we look at adjusted-close returns over the next 240 trading days by valuation regime.

PE percentile bandSample days240-day avg returnMedianWin rateAvg excess (vs index)
0-20 112+17.8% +22.4% 87.5% -13.9%
20-40 You are here259-0.4% -9.6% 45.9% -26.3%
40-60 177+9.4% +7.5% 62.1% -17%
60-80 345+11.8% +7.8% 52.2% -18.3%
80-100 423+21.8% +27.3% 62.4% +4%

Percentiles use an expanding own-history window (no look-ahead); forward return is 240 trading days on adjusted close. Sample days overlap; distribution is indicative only.

Current PE ≈ 24.11, at the 38.5th percentile of its own history (20-40 band).

Valuation × momentum historical grid

Every day in its own history is bucketed by valuation tercile (own-history PE) and 60-day momentum sign into six cells; we show adjusted-close returns over the next 120 trading days per cell.

Valuation
Momentum
Cheap (own-history bottom 1/3)
Mid
Expensive (own-history top 1/3)
60-day momentum up
+0.5%
Win rate 56.3% Excess -8.5%
167d
+8.4%
Win rate 63% Excess -12.4%
246d
-6.6%
Win rate 34.6% Excess -22.6%
318d
60-day momentum down
-1.1%
Win rate 39% Excess -4.8%
223d
Now
+29.2%
Win rate 52.4% Excess +16.7%
147d
+7.2%
Win rate 47.2% Excess -9.8%
335d

Currently in “Mid × 60-day momentum down”: across 147 historical days, 120-day forward avg gained 29.2%, win rate 52.4%, beat the market by 16.7%.

Days = trading days in this bucket; returns use adjusted prices, ex-costs. 60-day momentum: direction of this stock's price over the past 60 trading days.

Does this signal hold up across the market

Over the past 242 months, on average ~404 stocks per month met “monthly revenue YoY ≥ 20%”; their adjusted-close return over the next 60 trading days averaged 6.94% (equal-weighted), beating the market by 2.37 points on average, and outperformed the TAIEX total-return index in 64.5% of months.

Each month, equal-weighted 60-day forward adjusted return of all signal-matching stocks, then averaged across months; excess vs the TAIEX total-return index.

Signals not active (historical stats for reference)

These are not occurring now; historical samples shown for comparison.

252-day price high (breakout)

Pending

Adjusted close makes a new 252-day high; repeats within 20 days counted once.

17 times historically; 60-day forward avg +7.03%, win rate 64.7%, beating the market by +0.95 pts on average.

Foreign net buying for 5 straight days

Pending

Foreign net flow (ex-dealer) positive for 5 straight days; event on day 5; repeats within 20 days counted once.

24 times historically; 60-day forward avg +0.53%, win rate 33.3%, beating the market by -2.82 pts on average.

What does 永日 do? Company profile

生技醫療業；原料藥、賦形劑、醫藥中間體、特用化學品與CDMO/CMO 櫃買中心上櫃

Overview

4102 對應永日化學工業股份有限公司，為櫃買中心上櫃普通股。公司成立於 1978 年 6 月 8 日，1997 年 7 月 2 日公開發行，2001 年 3 月 20 日上櫃掛牌；總部/工廠位於台中市大甲區日南里幼獅路 59、61 號。依公開資訊與 113 年度財報，實收資本額約新台幣 423,734,430 元，普通股 42,373,443 股；113 年度合併營收 583,695 仟元、稅後淨利 70,049 仟元、EPS 1.52 元。董事長為林青煌，公開資訊亦顯示總經理/發言人為李育儒；公司治理資料顯示董事長兼任總經理之組織調整於 114 年底前完成，職稱資訊可能因公告時間點而有差異。113 年底員工約 141 人，平均年齡約 42.05 歲、平均服務年資約 11.54 年。主要股東/法人董事包含永信國際投資控股股份有限公司、永銓投資股份有限公司等；券商資訊揭露永信國際投資控股持股約 7,544,302 股，永銓投資約 1,074,000 股，顯示永日屬永信集團體系。公司持有重要子公司台灣味群工業股份有限公司，跨足健康食品與食品代工。

Business

永日核心業務是人用原料藥 API、賦形劑、醫藥中間體、特用/精細化學品，以及原料藥受託開發與製造 CDMO/CMO。公司官網列示商業化產品包含 Acyclovir、Clonidine Hydrochloride、Deferasirox、Diclofenac Acid/Potassium/Sodium、Econazole Nitrate、Mefenamic Acid、Metoprolol Succinate、Miconazole Base/Nitrate、Mirabegron、Sacubitril Valsartan Sodium、Sodium Starch Glycolate、Valacyclovir、Zolpidem Tartrate 等，另有 Prilocaine、Rivaroxaban、Tolvaptan 處於確效階段，Daprodustat、Ertugliflozin、Finerenone、Upadacitinib、Tenapanor、Vibegron 等處於開發階段。公司已取得/通過 FDA、MHRA、PMDA、IPEA、KFDA、TFDA PIC/S GMP 等國際品質與查廠認證，產品在台灣、美國、加拿大、日本及歐盟進行 DMF 登記，客戶分布全球，主要面向國內外製劑藥廠、新藥公司、代理商與特化品材料客戶。依 MoneyDJ 與公司資料，截至 2024 年營收結構約為原料藥 55%、賦形劑 29%；公司 2025 法說資料另揭露 2024 年原料藥營收占比 62.6%、代工與特化品合計 20.9%、台灣味群健康食品/食品代工約 16.5%，兩組分類口徑不同但方向一致，即原料藥仍為主體，CDMO/CMO、特化品與食品代工為第二成長曲線。商業模式包括自有 API/賦形劑銷售、替客戶完成製程開發/確效/量產/DMF 或 ANDA 原料文件支援、與新藥公司及製劑廠共同開發，以及利用既有 GMP 品質系統切入特用化學品。

Outlook 2025–2028

2025 至 2028 年展望以『原料藥本業產品線擴張 + CDMO/CMO + 特用化學品 + 子公司食品代工』為主軸。成長動能方面，全球 API 市場受高齡化、慢性病、學名藥與高附加價值療法需求支撐；公司 2025 法說引用全球 API 市場 2025 年約 2,300 至 2,500 億美元、年均成長率約 6%，2026 年可望突破 2,520 億美元。公司策略包含開發 5 至 10 年內專利到期且具利基/技術門檻的 API、推動新產品配合製劑登記與 DMF 送審、強化日歐美既有客戶並開發歐洲與非洲市場。產品與研發節點方面，113 年報揭露與客戶共同開發的心衰竭治療 API 已完成確效，膀胱過動症與局部麻醉劑 API 預計於 114 年提出查驗登記與 GMP 查核；2025 法說指出 2025 年申請藥證 1 張、2026 年預計申請 2 張藥證，2026 年預計 3 支新產品進入確效階段，並持續爭取新藥公司合作開發案。特化品方面，113 年報指出透過異業合作發展 3 項特化品，待客戶測試後規劃量產；2023 年公司對外說明特化品客戶主要來自台灣光電及半導體相關廠商，具國產替代與供應鏈分散題材。CDMO/CMO 方面，113 年度營收年增 11.8%，後續若臨床/商業化客戶推進順利，可提升產能利用率與毛利結構。風險與挑戰包括中國與印度 API 低成本競爭、原材料/能源價格波動、貿易戰與供應鏈中斷、美國進口藥品關稅或反傾銷/出口限制等政策不確定性、國際藥政法規與品質標準變化、客戶臨床時程與庫存調整造成訂單波動、特化品客戶驗證轉量產不確定性，以及公司規模相對大型國際 API 廠小、需透過品質與高法規市場服務維持差異化。2027 至 2028 的具體財務目標未見公司明確量化揭露；上述展望中 2027 至 2028 部分屬依公司產品開發週期與策略方向的推估。

Supply Chain

Upstream
  • 國內外化工原料、溶劑、醫藥中間體供應商 永日上游主要為 API 合成所需化工原料、溶劑與中間體；年報揭露原材料價格、能源價格、貿易戰與供應鏈中斷會影響成本與供應穩定，但未具名主要供應商。
  • 製藥設備、檢驗儀器與 GMP/品質系統服務供應商 原料藥生產與品管需要反應、乾燥、純化、分析檢驗等設備及法規品質系統；公司官網揭露具備 GC、HPLC、IR、UV、ICP-OES、粒徑分析等品管設備，但未揭露具名設備供應商。
  • 永信國際投資控股股份有限公司 3705 永信集團法人股東與資源整合平台；永信投控持有永信藥品，並為永日主要法人董事/股東之一，屬集團資源與治理關係，非單純原料供應商。
Downstream
  • 國內外製劑藥廠與學名藥公司 永日 API、賦形劑與中間體銷售對象；公司官網指出客戶分布全球，並為製劑廠提供符合 GLP/GMP 的原料藥代工、量產、DMF/ANDA 原料文件支援。具名客戶多未公開。
  • 新藥公司與 CDMO/CMO 客戶 永日與新藥公司合作進行新藥開發、生產與臨床/商業化前 API 供應；113 年報揭露 CDMO/CMO 營收年增 11.8%，但未揭露具名客戶。
  • 永信國際投資控股股份有限公司/永信藥品體系 3705 永日早期設立目的包含供應原料藥予永信藥品，現屬永信集團體系；永信藥品已轉型由永信投控持有，故以 3705 標示集團上市主體。
  • 台灣光電、半導體與材料廠商 特用化學品下游客戶類型；公開報導稱特化品客戶主要為台灣光電及半導體廠商，部分產品仍在客戶測試或小量訂單轉換階段，未揭露具名公司。
  • 台灣味群工業股份有限公司 永日重要子公司，未上市；從事健康食品、食品製造與代工包裝，113 年度子公司營收占永日合併營收約 16.5%，屬集團多角化下游/旁支業務。

Competitors

Sources（13）

This company profile is compiled from public sources (annual reports, filings, news and analyst reports), not finlab backtest data; the 2025–2028 outlook contains forward-looking estimates and is for reference only.

Method and limitations

  • All returns use adjusted close (etl:adj_close), already adjusted for dividends and splits.
  • Excess return is measured against the TAIEX total-return index (dividends included).
  • Valuation regime and percentile stats use an expanding own-history window (no future data).
  • Revenue-signal event dates align to the first trading day after the filing deadline, avoiding look-ahead.
  • Event samples may overlap in time; stats describe historical distribution only and are less reliable when samples are few.

This page is historical statistics for educational purposes and is not investment advice. Investing involves risk; past performance does not indicate future results. Assess and bear the risk yourself before trading.